Masuko T, Sugahara K, Kamiya T, Hashimoto Y
Department of Hygienic Chemistry, Tohoku University, Sendai, Japan.
Int J Cancer. 1989 Oct 15;44(4):582-8. doi: 10.1002/ijc.2910440404.
Monoclonal antibodies (MAbs) were obtained from hybridoma clones established by cell fusion between P3X63Ag8.653 mouse myeloma cells and spleen cells of mice or rats hyperimmunized against human bladder cancer tissue or BC47 rat bladder cancer cells. RBS-31 and RBS-85 mouse MAbs and RBA-1 rat MAb were raised against BC47 cells and HBP-1 MAb was raised against human bladder cancer tissues. Urinary antigens detected by these MAbs were quantitatively assayed by means of ELISA using 50 microliters of 1:2 diluted urine samples. The cut-off value of the assay was set up as the mean + 4 X SD of the mean using data from the healthy individual urine samples. The reactivity of all healthy control urine samples were under the cut-off value (negative). By contrast, urine from bladder cancer patients reacted positively with the RBS-31 MAb at 72%, with the RBS-85 MAb at 63%, with the RBA-1 MAb at 51% and with the HBP-1 MAb at 35%. The urine samples from some patients with renal calculi, acute cystitis or complicated urinary tract infections showed only a weak reactivity with our MAbs. As for extra-bladder cancers, some patients with renal, renal pelvis, prostate or ureter cancer, but no patients with esophageal, gastric, colon or liver cancer or leukemia, had reactive urinary antigens.
单克隆抗体（MAb）是从杂交瘤克隆中获得的，这些克隆是通过将P3X63Ag8.653小鼠骨髓瘤细胞与针对人膀胱癌组织或BC47大鼠膀胱癌细胞进行超免疫的小鼠或大鼠的脾细胞进行细胞融合而建立的。RBS - 31和RBS - 85小鼠单克隆抗体以及RBA - 1大鼠单克隆抗体是针对BC47细胞产生的，而HBP - 1单克隆抗体是针对人膀胱癌组织产生的。使用这些单克隆抗体检测到的尿液抗原通过酶联免疫吸附测定（ELISA）进行定量分析，使用50微升1:2稀释的尿液样本。该检测的临界值设定为使用健康个体尿液样本数据的平均值 + 4×标准差。所有健康对照尿液样本的反应性均低于临界值（阴性）。相比之下，膀胱癌患者的尿液与RBS - 31单克隆抗体的反应阳性率为72%，与RBS - 85单克隆抗体的反应阳性率为63%，与RBA - 1单克隆抗体的反应阳性率为51%，与HBP - 1单克隆抗体的反应阳性率为35%。一些肾结石、急性膀胱炎或复杂性尿路感染患者的尿液样本与我们的单克隆抗体仅表现出微弱反应。至于膀胱外癌症，一些肾癌、肾盂癌、前列腺癌或输尿管癌患者有反应性尿液抗原，但食管癌、胃癌、结肠癌、肝癌或白血病患者没有。
